Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AtriCure, Inc. stock logo
ATRC
AtriCure
$32.74
+2.6%
$32.51
$20.20
$43.11
$1.58B1.59620,987 shs223,518 shs
Axonics, Inc. stock logo
AXNX
Axonics
$70.98
$70.61
$67.01
$71.05
$3.63B0.82420,168 shsN/A
ICU Medical, Inc. stock logo
ICUI
ICU Medical
$130.88
+2.2%
$134.53
$111.97
$196.26
$3.15B0.88271,437 shs152,831 shs
NovoCure Limited stock logo
NVCR
NovoCure
$17.00
+2.3%
$17.55
$14.17
$34.13
$1.85B0.741.19 million shs2.52 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AtriCure, Inc. stock logo
ATRC
AtriCure
+1.59%-1.27%-2.48%-8.46%+39.06%
Axonics, Inc. stock logo
AXNX
Axonics
0.00%0.00%0.00%0.00%+5.05%
ICU Medical, Inc. stock logo
ICUI
ICU Medical
+0.26%-3.88%-0.71%-14.55%+10.31%
NovoCure Limited stock logo
NVCR
NovoCure
-0.48%-7.26%-10.41%-11.51%-12.90%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AtriCure, Inc. stock logo
ATRC
AtriCure
3.6929 of 5 stars
4.53.00.00.02.62.50.6
Axonics, Inc. stock logo
AXNX
Axonics
N/AN/AN/AN/AN/AN/AN/AN/A
ICU Medical, Inc. stock logo
ICUI
ICU Medical
4.5737 of 5 stars
3.53.00.03.92.22.51.9
NovoCure Limited stock logo
NVCR
NovoCure
4.3044 of 5 stars
3.34.00.04.53.51.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AtriCure, Inc. stock logo
ATRC
AtriCure
3.00
Buy$50.6754.75% Upside
Axonics, Inc. stock logo
AXNX
Axonics
2.00
HoldN/AN/A
ICU Medical, Inc. stock logo
ICUI
ICU Medical
3.00
Buy$192.6747.21% Upside
NovoCure Limited stock logo
NVCR
NovoCure
2.67
Moderate Buy$32.8393.14% Upside

Current Analyst Ratings Breakdown

Latest AXNX, NVCR, ICUI, and ATRC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/9/2025
ICU Medical, Inc. stock logo
ICUI
ICU Medical
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetStrong-Buy ➝ Strong-Buy$197.00 ➝ $187.00
4/30/2025
AtriCure, Inc. stock logo
ATRC
AtriCure
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$60.00 ➝ $60.00
4/30/2025
AtriCure, Inc. stock logo
ATRC
AtriCure
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$60.00 ➝ $58.00
4/30/2025
AtriCure, Inc. stock logo
ATRC
AtriCure
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$51.00 ➝ $44.00
4/23/2025
NovoCure Limited stock logo
NVCR
NovoCure
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$42.00 ➝ $34.00
4/21/2025
ICU Medical, Inc. stock logo
ICUI
ICU Medical
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$209.00 ➝ $191.00
4/16/2025
NovoCure Limited stock logo
NVCR
NovoCure
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$29.00 ➝ $27.00
4/10/2025
NovoCure Limited stock logo
NVCR
NovoCure
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$29.00 ➝ $28.00
4/8/2025
ICU Medical, Inc. stock logo
ICUI
ICU Medical
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
3/28/2025
AtriCure, Inc. stock logo
ATRC
AtriCure
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$66.00 ➝ $52.00
3/27/2025
AtriCure, Inc. stock logo
ATRC
AtriCure
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AtriCure, Inc. stock logo
ATRC
AtriCure
$465.31M3.48N/AN/A$9.46 per share3.46
Axonics, Inc. stock logo
AXNX
Axonics
$366.38M9.90$0.13 per share561.96$12.59 per share5.64
ICU Medical, Inc. stock logo
ICUI
ICU Medical
$2.38B1.35$14.34 per share9.13$80.26 per share1.63
NovoCure Limited stock logo
NVCR
NovoCure
$605.22M3.13N/AN/A$3.33 per share5.11
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AtriCure, Inc. stock logo
ATRC
AtriCure
-$44.70M-$0.81N/AN/AN/A-7.95%-5.68%-4.34%7/29/2025 (Estimated)
Axonics, Inc. stock logo
AXNX
Axonics
-$6.09M-$0.12N/A80.66N/A-1.31%0.36%0.31%N/A
ICU Medical, Inc. stock logo
ICUI
ICU Medical
-$117.69M-$3.83N/A24.06N/A-3.87%6.75%3.20%8/6/2025 (Estimated)
NovoCure Limited stock logo
NVCR
NovoCure
-$168.63M-$1.51N/AN/AN/A-26.41%-45.46%-13.34%7/24/2025 (Estimated)

Latest AXNX, NVCR, ICUI, and ATRC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
ICU Medical, Inc. stock logo
ICUI
ICU Medical
$1.23$1.72+$0.49-$0.63$574.15 million$599.49 million
4/29/2025Q1 2025
AtriCure, Inc. stock logo
ATRC
AtriCure
-$0.25-$0.14+$0.11-$0.14$122.92 million$123.62 million
4/24/2025Q1 2025
NovoCure Limited stock logo
NVCR
NovoCure
-$0.47-$0.31+$0.16-$0.31$147.57 million$154.99 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AtriCure, Inc. stock logo
ATRC
AtriCure
N/AN/AN/AN/AN/A
Axonics, Inc. stock logo
AXNX
Axonics
N/AN/AN/AN/AN/A
ICU Medical, Inc. stock logo
ICUI
ICU Medical
N/AN/AN/AN/AN/A
NovoCure Limited stock logo
NVCR
NovoCure
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AtriCure, Inc. stock logo
ATRC
AtriCure
0.16
4.11
2.88
Axonics, Inc. stock logo
AXNX
Axonics
N/A
8.16
6.40
ICU Medical, Inc. stock logo
ICUI
ICU Medical
0.75
2.59
1.52
NovoCure Limited stock logo
NVCR
NovoCure
0.27
1.47
1.41

Institutional Ownership

CompanyInstitutional Ownership
AtriCure, Inc. stock logo
ATRC
AtriCure
99.11%
Axonics, Inc. stock logo
AXNX
Axonics
99.48%
ICU Medical, Inc. stock logo
ICUI
ICU Medical
96.10%
NovoCure Limited stock logo
NVCR
NovoCure
84.61%

Insider Ownership

CompanyInsider Ownership
AtriCure, Inc. stock logo
ATRC
AtriCure
3.50%
Axonics, Inc. stock logo
AXNX
Axonics
1.85%
ICU Medical, Inc. stock logo
ICUI
ICU Medical
1.50%
NovoCure Limited stock logo
NVCR
NovoCure
5.52%
CompanyEmployeesShares OutstandingFree FloatOptionable
AtriCure, Inc. stock logo
ATRC
AtriCure
1,30049.51 million47.77 millionOptionable
Axonics, Inc. stock logo
AXNX
Axonics
61051.11 million50.16 millionOptionable
ICU Medical, Inc. stock logo
ICUI
ICU Medical
15,00024.61 million24.24 millionOptionable
NovoCure Limited stock logo
NVCR
NovoCure
1,488111.49 million105.33 millionOptionable

Recent News About These Companies

Novocure Announces Upcoming Investor Events

New MarketBeat Followers Over Time

Media Sentiment Over Time

AtriCure stock logo

AtriCure NASDAQ:ATRC

$32.74 +0.84 (+2.63%)
Closing price 04:00 PM Eastern
Extended Trading
$32.74 0.00 (0.00%)
As of 04:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Axonics stock logo

Axonics NASDAQ:AXNX

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

ICU Medical stock logo

ICU Medical NASDAQ:ICUI

$130.88 +2.81 (+2.19%)
Closing price 04:00 PM Eastern
Extended Trading
$130.84 -0.04 (-0.03%)
As of 04:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.

NovoCure stock logo

NovoCure NASDAQ:NVCR

$17.00 +0.39 (+2.35%)
Closing price 04:00 PM Eastern
Extended Trading
$16.98 -0.02 (-0.09%)
As of 05:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.